BTK and autoimmune thrombocytopenic purpura: In a study of ITP patients who were refractory to multiple anti-inflammatory treatments with no alternative therapeutic options, the BTK inhibitor rilzabrutinib demonstrated improvement as measured by an increase in platelet counts in subjects treated for a median period of 10 weeks (86).